An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic prostate cancer previously treated and castrated with a GnRH analogue
Latest Information Update: 21 Sep 2024
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TriptoSwitch
- Sponsors Ipsen Pharmaceuticals
Most Recent Events
- 01 Aug 2024 Status changed from active, no longer recruiting to completed.
- 23 Jul 2024 This trial has been completed in Netherlands, Czechia, and France according to European Clinical Trials Database record.
- 23 Jun 2024 This trial has been completed in Greece, according to European Clinical Trials Database record.